Abstract
Because of its biological heterogeneity and wide spectrum of responsiveness to different treatments, breast cancer is a complex disease of difficult clinical management. Over the past several years, knowledge of the molecular mechanisms regulating normal and aberrant cell growth leading to cancer has been enhanced. These advances have enabled the identification of an increasing number of surrogate biomarkers, which have been correlated with prognosis or used as predictors of response to specific treatments. Axillary nodal status, age, tumor size, pathologic grade, and hormone receptor status are the established prognostic and/or predictive factors for selection of adjuvant treatments. The role of new biomarkers, such as p53, HER2/neu, angiogenesis, and the proliferation index value, is promising; however, the clinical value of their determination must be provided by prospective clinical studies.
| Original language | English |
|---|---|
| Pages (from-to) | 381-390 |
| Number of pages | 10 |
| Journal | Clinical Breast Cancer |
| Volume | 3 |
| Issue number | 6 |
| Publication status | Published - 2003 |
Fingerprint
Keywords
- Angiogenesis
- Axillary nodal status
- Biomarkers
- HER2/neu
- Hormone receptor
- p53
- Proliferation index
ASJC Scopus subject areas
- Cancer Research
Cite this
Prognostic and predictive indicators in operable breast cancer. / Morabito, Alessandro; Magnani, Elena; Gion, Massimo; Sarmiento, Roberta; Capaccetti, Barbara; Longo, Raffaele; Gattuso, Domenico; Gasparini, Giampietro.
In: Clinical Breast Cancer, Vol. 3, No. 6, 2003, p. 381-390.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic and predictive indicators in operable breast cancer
AU - Morabito, Alessandro
AU - Magnani, Elena
AU - Gion, Massimo
AU - Sarmiento, Roberta
AU - Capaccetti, Barbara
AU - Longo, Raffaele
AU - Gattuso, Domenico
AU - Gasparini, Giampietro
PY - 2003
Y1 - 2003
N2 - Because of its biological heterogeneity and wide spectrum of responsiveness to different treatments, breast cancer is a complex disease of difficult clinical management. Over the past several years, knowledge of the molecular mechanisms regulating normal and aberrant cell growth leading to cancer has been enhanced. These advances have enabled the identification of an increasing number of surrogate biomarkers, which have been correlated with prognosis or used as predictors of response to specific treatments. Axillary nodal status, age, tumor size, pathologic grade, and hormone receptor status are the established prognostic and/or predictive factors for selection of adjuvant treatments. The role of new biomarkers, such as p53, HER2/neu, angiogenesis, and the proliferation index value, is promising; however, the clinical value of their determination must be provided by prospective clinical studies.
AB - Because of its biological heterogeneity and wide spectrum of responsiveness to different treatments, breast cancer is a complex disease of difficult clinical management. Over the past several years, knowledge of the molecular mechanisms regulating normal and aberrant cell growth leading to cancer has been enhanced. These advances have enabled the identification of an increasing number of surrogate biomarkers, which have been correlated with prognosis or used as predictors of response to specific treatments. Axillary nodal status, age, tumor size, pathologic grade, and hormone receptor status are the established prognostic and/or predictive factors for selection of adjuvant treatments. The role of new biomarkers, such as p53, HER2/neu, angiogenesis, and the proliferation index value, is promising; however, the clinical value of their determination must be provided by prospective clinical studies.
KW - Angiogenesis
KW - Axillary nodal status
KW - Biomarkers
KW - HER2/neu
KW - Hormone receptor
KW - p53
KW - Proliferation index
UR - http://www.scopus.com/inward/record.url?scp=0037303970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037303970&partnerID=8YFLogxK
M3 - Article
C2 - 12636883
AN - SCOPUS:0037303970
VL - 3
SP - 381
EP - 390
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
IS - 6
ER -